Impact of observed versus hypothesized service utilization on the incremental cost of first trimester screening and prenatal diagnosis for trisomy 21 in a Canadian province

Prenatal Diagnosis

Volumn 33, Issue 5, 2013, Pages 429-435

  Metcalfe, Amy ^a   Currie, Gillian ^b,c   Johnson, Jo Ann ^c   Bernier, Francois ^d   Lix, Lisa M ^e   Lyon, Andrew W ^f   Tough, Suzanne C ^b,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d ALBERTA CHILDREN'S HOSPITAL   (Canada)

^e UNIVERSITY OF MANITOBA   (Canada)

^f UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANADA; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DATA BASE; ECONOMIC EVALUATION; FEMALE; FIRST TRIMESTER PREGNANCY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HYPOTHESIS; OBSERVATIONAL METHOD; PREGNANCY TERMINATION; PRENATAL CARE; PRENATAL DIAGNOSIS; PRENATAL SCREENING; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; TRISOMY 21;

ADULT; CANADA; COST-BENEFIT ANALYSIS; DOWN SYNDROME; FEMALE; HEALTH CARE COSTS; HUMANS; MASS SCREENING; OBSERVATION; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PRENATAL DIAGNOSIS;

EID: 84877627860     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.4082     Document Type: Article

References (46)

1. Audibert F, Gagnon A. Prenatal screening for and diagnosis of aneuploidy in twin pregnancies. J Obstet Gynaecol Can 2011;33(7):754-67.
2. Chitayat D, Langlois S, Wilson RD. Prenatal screening for fetal aneuploidy in singleton pregnancies. J Obstet Gynaecol Can 2011;33(7):736-50.
3. Summers AM, Langlois S, Wyatt P, Wilson RD. Prenatal screening for fetal aneuploidy. J Obstet Gynaecol Can 2007;29(2):146-79.
4. Caughey AB, Kaimal AJ, Odibo AO. Cost-effectiveness of down syndrome screening paradigms. Clin Lab Med 2010;30:629-42.
5. Caughey AB, Kuppermann M, Norton ME, Washington AE. Nuchal translucency and first trimester biochemical markers for down syndrome screening: a cost-effectiveness analysis. Am J Obstet Gynecol 2002;187(5):1239-45.
6. Gekas J, Gagne G, Bujold E, Douillard D, Forest JC, Reinharz D, et al. Comparison of different strategies in prenatal screening for Down's syndrome: cost effectiveness analysis of computer simulation. BMJ 2009;338(b138).
7. Harris AH. The cost effectiveness of prenatal ultrasound screening for trisomy 21. Int J Technol Assess Health Care 2004;20(4):464-8.
8. Kott B, Dubinsky TJ. Cost-effectiveness model for first-trimester versus second-trimester ultrasound screening for Down syndrome. J Am Coll Radiol 2004;1(6):415-21.
9. Macones GA, Odibo A. First trimester screening: economic implications. Semin Perinatol 2005;29(4):263-6.
10. Cusick W, Vintzileos AM. Fetal Down syndrome screening: a cost effectiveness analysis of alternative screening programs. J Matern Fetal Med 1999;8(6):243-8.
11. Cusick W, Buchanan P, Hallahan TW, Krantz DA, Larsen JW, Jr., Macri JN. Combined first-trimester versus second-trimester serum screening for Down syndrome: a cost analysis. Am J Obstet Gynecol 2003;188(3):745-51.
12. Hartnett J, Borgida AF, Benn PA, Feldman DM, DeRoche ME, Egan JF. Cost analysis of Down syndrome screening in advanced maternal age. J Matern Fetal Neonatal Med 2003;13(2):80-4.
13. Biggio JR, Jr., Morris TC, Owen J, Stringer JS. An outcomes analysis of five prenatal screening strategies for trisomy 21 in women younger than 35 years. Am J Obstet Gynecol 2004;190(3):721-9.
14. Beazoglou T, Heffley D, Kyriopoulos J, Vintzileos A, Benn P. Economic evaluation of prenatal screening for Down syndrome in the U.S.A. Prenat Diagn 1998;18(12):1241-52.
15. Ritchie K, Bradbury I, Slattery J, Wright D, Iqbal K, Penney G. Economic modelling of antenatal screening and ultrasound scanning programmes for identification of fetal abnormalities. BJOG 2005;112(7):866-74.
16. Vintzileos AM, Ananth CV, Smulian JC, Day-Salvatore DL, Beazoglou T, Knuppel RA. Cost-benefit analysis of prenatal diagnosis for Down syndrome using the British or the American approach. Obstet Gynecol 2000;95(4):577-83.
17. Ball RH, Caughey AB, Malone FD, Nyberg DA, Comstock CH, Saade GR, et al. First- and Second-Trimester Evaluation of Risk for Down Syndrome. Obstet Gynecol 2007;110(1):10-7.
18. Petrou S, Henderson J, Roberts T, Martin MA. Recent economic evaluations of antenatal screening: a systematic review and critique. J Med Screen 2000;7(2):59-73.
19. Shackley P. Economic evaluation of prenatal diagnosis: a methodological review. Prenat Diagn 1996;16(5):389-95.
20. Chen Y, Qian X, Li J, Zhang J, Chu A, Schweitzer SO. Cost-effectiveness analysis of prenatal diagnosis intervention for Down's syndrome in China. Int J Technol Assess Health Care 2007;23(1):138-45.
21. Chou CY, Hsieh FJ, Cheong ML, Lee FK, She BQ, Tsai MS. First trimester Down syndrome screening in women younger than 35 years old and cost-effectiveness analysis in Taiwan population. J Eval Clin Pract 2009;15:789-96.
22. Cunningham GC, Tompkinson DG. Cost and effectiveness of the California triple marker prenatal screening program. Genet Med 1999;1(5):200-7.
23. Garrouste C, Le J, Maurin E. The choice of detecting Down syndrome: does money matter? Health Econ 2011;20:1073-89.
24. Hoogendoorn M, Evers SMAA, Schielen PCJI, van Genugten MLL, de Wit GA, Ament AJHA. Costs and effects of prenatal methods for Down syndrome and neural tube defects. Community Genet 2008;11:359-67.
25. Odibo A, Stamilio DM, Nelson DB, Sehdev HM, Macones GA. A cost-effectiveness analysis of prenatal screening strategies for Down syndrome. Obstet Gynecol 2005;106(3):562-8.
26. Gekas J, Durant A, Bujold E, Vallee M, Forest JC, Rousseau F, et al. Cost-effectiveness and accuracy of prenatal Down syndrome screening strategies: should the combined test continue to be widely used? Am J Obstet Gynecol 2011;204(175):e1-e8.
27. Grosse SD. Does newborn screening save money? The difference between cost-effective and cost-saving interventions. J Pediatr 2005;146:168-70.
28. Orlandi F, Damiani G, Hallahan TW, Krantz DA, Macri JN. First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency. Ultrasound Obstet Gynecol 1997;10:381-6.
29. Johnson J, Pastuck M. ERA Program Performance 2006-2011. Early Risk Assessment Program Scientific Day; Calgary 2011.
30. Leslie WD, Metge CJ, Azimaee M, Lix LM, Finlayson GS, Morin SN, et al. Direct costs of fractures in Canada and trends 1996-2006: a population-based cost-of-illness analysis. J Bone Miner Res 2011;26(10):2419-29.
31. Kuppermann M, Learman LA, Gates E, Gregorich SE, Nease RFJ, Lewis J, et al. Beyond race or ethnicity and socioeconomic status: predictors of prenatal testing for Down syndrome. Obstet Gynecol 2006;107:1087-97.
32. Burton P, Lethbridge L, Phipps S. Mothering children with disabilities and chronic conditions: long-term implications for self-reported health. Canadian Public Policy 2008;34(3):359-78.
33. Burton P, Phipps S. Economic costs of caring for children with disabilities in Canada. Canadian Public Policy 2009;35(3):269-90.
34. Heaman DJ. Perceived stressors and coping strategies of parents who have children with developmental disabilities: a comparison of mothers with fathers. J Pediatr Nurs 1995;10(5):311-20.
35. Pelchat D, Lefebvre H, Perreault M. Differences and similarities between mothers' and fathers' experiences of parenting a child with a disability. J Child Health Care 2003;7(4):231-47.
36. Lee A, Rempel GR. Parenting children with hypoplastic left heart syndrome: finding a balance. J Spec Pediatr Nurs 2011;16:179-89.
37. Hippman C, Inglis A, Austin J. What is a 'balanced' description? Insight from parents of individuals with Down Syndrome. J Genet Counsel 2012;21:35-44.
38. Kuppermann M, Nease RFJ, Learman LA, Gates E, Blumberg B, Washington AE. Procedure-related miscarriages and Down syndrome-affected births: implications for prenatal testing based on women's preferences. Obstet Gynecol 2000;96:511-6.
39. Kuppermann M, Goldberg JD, Nease RF, Washington AE. Who should be offered prenatal diagnosis? The 35-year-old question. Am J Public Health 1999;89:160-3.
40. Canada Health Act, Stat. R.S.C. 1985, c. C-6 (1985).
41. Cavanagh J, Mathews M, Crane J. Awareness and use of maternal serum screening among women from the St. John's region of Newfoundland and Labrador. J Obstet Gynaecol Can 2007;29(8):630-4.
42. Public Health Agency of Canada. What Mothers Say: The Canadian Maternity Experiences Survey. Ottawa: 2009.
43. Xie F, Thumboo J, Li SC. True difference or something else? Problems in cost of osteoarthritis studies. Semin Arthritis Rheum 2007;37(2):127-32.
44. Alberta Health Care Insurance Plan. Medical Procedure List. Edmonton: Alberta Health and Wellness, 2012.
45. Alberta Health Care Insurance Plan. Medical Price List. Edmonton: Alberta Health and Wellness, 2012.
46. Medical Services Comission. Laboratory Services. Victoria: British Columbia Ministry of Health, 2012.